FIG 3.

In vivo Candida glabrata ATCC 2001 (WT) and Candida glabrata lucOPT 7/2/4 biofilm formation studied by longitudinal BLI. (A) In vivo BLI of C. glabrata biofilm formation after implant (90 min, period of adhesion) and 1, 5, and 7 days of biofilm formation. Three polyurethane devices infected with C. glabrata ATCC 2001 (WT) strain were implanted on left side of the back, whereas 3 devices challenged with lucOPT 7/2/4 were inserted on the ride side of the back of the animal. (B) Quantification of bioluminescence signal intensity acquired at different time points (adhesion, 1, 5, and 7 days, n = 6 animals per time point, except for a group with noninfected catheters with n = 1) of noninfected devices (black columns), C. glabrata ATCC 2001 (gray columns), and C. glabrata lucOPT 7/2/4 (white columns) biofilm formation. (C) CFU counts retrieved from catheters infected with C. glabrata ATCC 2001 (black columns) and with C. glabrata lucOPT 7/2/4 (white columns) after adhesion and 1, 5, and 7 days of in vitro biofilm formation inside polyurethane devices. (C) A BLI signal intensity retrieved after adhesion (90 min) and later stages of biofilm formation. Statistical analyses were performed using the two-way ANOVA with post hoc Tukey’s HSD test. Differences were considered significant at *P values of ≤0.05, and error bars indicate SEM of replicate samples.